Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proteomic-based randomized study of second-line erlotinib versus chemotherapy in advanced non-small cell lung cancer
2007-006299-13Phase 3Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Dec 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of erlotinib, pemetrexed and docetaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Progression-free survival. Started Dec 2007; status: completed.
02
Drugs
erlotinibpemetrexeddocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-006299-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006299-13.